Accelerating GPRC5D Therapy: Proteins, mAbs and CAR-T
GPRC5D plays a pivotal role in cancer and immunology research, garnering significant industry attention. At DIMA Biotechnology, we provide essential tools for exploring this promising target. Our offerings include functional active proteins and specialized antibodies, with a particular focus on GPRC5D CAR-T molecules, which have progressed from leads to Investigator-Initiated Trial (IIT) clinical trial stages in collaboration with our partners. Preliminary data from ongoing clinical trials showcase remarkable clinical efficacy, particularly in treating RRMM patients. Our proprietary technology platforms streamline drug discovery processes, offering comprehensive support to expedite therapeutic research and development.
In recent developments, LaNova’s LM-305, an ADC targeting GPRC5D, secured an exclusive global license with AstraZeneca, resulting in an immediate payment of $55 million and the potential for milestone payments totaling $545 million. Concurrently, OriCell Therapeutics introduced OriCAR-017, marking China’s first CAR-T cell therapy designed to target GPRC5D. Additionally, Janssen’s talquetamab, a GPRC5D/CD3 bispecific antibody, displayed promising results in treating RRMM patients, with an anticipated U.S. launch as early as 2024. These advancements underscore the dynamic landscape of GPRC5D-targeted drugs and their potential to revolutionize the pharmaceutical industry.